1 / 9

IBD: Issues With Menstruation and Contraception

IBD: Issues With Menstruation and Contraception . Menstrual Cycle and Bowel-Pattern Fluctuations. Bowel-pattern fluctuation is common during the menstrual cycle IBD symptoms may increase during the menstrual cycle

emily
Download Presentation

IBD: Issues With Menstruation and Contraception

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IBD:Issues With Menstruation and Contraception

  2. Menstrual Cycle and Bowel-Pattern Fluctuations • Bowel-pattern fluctuation is common during the menstrual cycle • IBD symptoms may increase during the menstrual cycle • Suppression of menses via hormonal contraceptive methods may be considered in presence of debilitating symptoms

  3. Potential IBD-RelatedMenstrual Symptoms • Most frequently reported symptoms • Pelvic pain 52% • Lower back pain 36% • Diarrhea 26% • Irritability 23% • Headache 20% • Incidence of any menstrual symptoms significantly higher for IBD patients than for healthy controls (P.01) Kane SV, et al. Am J Gastroenterol. 1998;93:1867-1872.

  4. IBD: Issues With Menstruation • There is a trend for patients with CD to be affected by IBD symptoms during menstruation to a greater extent than are patients with UC • CD patients experienced diarrhea significantly more often than did controls (P=.004) Kane SV, et al. Am J Gastroenterol. 1998;93:1867-1872.

  5. OCs and IBD Risk • Controversial data • Increased incidence of CD with use of OCs? • OCs related to flare of CD activity? • Newer OCs with lower estrogen content associated with decreasing incidence of CD in women?

  6. CD Flare and OCs 60 50 40 OC use No OC use Patients With Flare (%) 30 20 10 0 0 100 200 300 400 500 Days After Inclusion Adapted from Cosnes J, et al. Gut. 1999;45:218-222 with permission from BMJ Publishing Group.

  7. OCs and IBD Risk 2.5 2.0 BaltimoreF:M incidencefor 20-29-year age group 1.5 OlmsteadF:M incidencefor 20-29-year age group F:M Incidence Ratio 1.0 US OC use(5 million) 0.5 0.0 1960 1965 1970 1975 1980 1985 1990 Adapted from Alic M. Gut. 2000;46:140 with permission from BMJ Publishing Group.

  8. Contraindications for OCs • History of thromboembolic disease • Active obstructive liver disease with elevated liver enzymes • Breast cancer • Smokers over the age of 35 • Pregnancy

  9. IBD and Contraception: Conclusions • OCs should have lower estrogen content (eg, 35 µg) • Avoid for women with known hypercoagulability • Avoid for women with IBD-associated liver disease • Avoid for women with IBD who smoke

More Related